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Abstract
Circadian clocks respond to environmental time cues
to coordinate 24-hour oscillations in almost every tissue
of the body. In the breast, circadian clocks regulate the
rhythmic expression of numerous genes. Disrupted
expression of circadian genes can alter breast biology
and may promote cancer. Here we overview circadian
mechanisms, and the connection between the
molecular clock and breast biology. We describe how
disruption of circadian genes contributes to cancer via
multiple mechanisms, and link this to increased tumour
risk in women who work irregular shift patterns.
Understanding the influence of circadian rhythms on
breast cancer could lead to more efficacious therapies,
reformed public health policy and improved patient
outcome.
Background
The global impact of breast cancer is large and growing.
With 1.67 million cases reported in 2012, it is the sec-
ond most commonly diagnosed cancer worldwide [1, 2].
The incidence of the disease is much higher in the de-
veloped world, with four times as many cases in Western
Europe as in Middle Africa and Eastern Asia. This
suggests that aspects of a modern western lifestyle may
influence the onset and progression of breast cancer.
One possibility is a disruption to our internal body
clocks, known as circadian clocks [3].
Intrinsic circadian clocks are driven by environmental
time cues such as the natural day/night cycle. Our bodies
translate timing cues into molecular oscillations within in-
dividual cells, which then drive 24-hour rhythms in cellu-
lar processes in almost every tissue in the body [4–6].
These cell-autonomous molecular oscillators make up the
body’s internal timing system, and are synchronized by the
master pacemaker, the suprachiasmatic nucleus (SCN) [7].
However, circadian clocks can become perturbed through
irregular shift work, through repeated bouts of jet lag and
during ageing. Weakened or damaged circadian clocks
alter the susceptibility to certain diseases and directly
drive others.
One of the processes regulated by the circadian clock
is the cell cycle. Disruption of circadian rhythms can
therefore be associated with abnormal cell divisions that
occur in cancer [8]. Indeed, there are links between al-
tered circadian clocks and tumorigenesis in metastatic
colorectal cancer, osteosarcoma, pancreatic adenocarcin-
oma and, most notably, breast cancer [8].
The influence of altered circadian rhythm on breast
cancer was first noted in the 1960s [9]. Since then, it has
become clear that circadian disruption interrupts the
complex multi-step molecular mechanisms underpin-
ning breast cancer [1]. The indication that tumorigenesis
is linked to circadian rhythms suggests that manipulat-
ing those rhythms might be a remedial approach for
treating cancer. This could, for example, lead to more ef-
ficacious therapies, novel adjuvant strategies and, ultim-
ately, improved breast cancer outcome [10].
In this review, we discuss the current understanding of
links between circadian disruption and breast cancer
risk.
The SCN as a central pacemaker
Located in the anterior hypothalamus, the SCN is the
central pacemaker that coordinates circadian rhythms with
the solar day [11]. The bilateral SCN receives innervation
directly from the retina via the retinohypothalamic tract.
The majority of its ~20,000 densely packed neurons are
‘pacemaker cells’, with each neuron containing its own
oscillatory machinery capable of producing a prolonged
and robust circadian rhythm even in ex-vivo culture [12].
Light is a dominant synchronizing time-giver. How-
ever as well as light/dark cycles, the SCN is also respon-
sive to changes in rest/activity cycles [5]. Non-photic
stimuli, such as neuroendocrine signals and feeding
behaviour, can also influence SCN pacemaking [5]. The
SCN uses several neural and endocrine outputs to
synchronize clocks of many peripheral organs [6]. One
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of these is the hormone melatonin [13], which is re-
leased rhythmically at night and relays information to
peripheral organs [14].
The SCN is not actually required for peripheral organs
to generate their own rhythms. Rather, it acts more like
the conductor of an orchestra, guiding each organ to os-
cillate in the ideal phase for that specific tissue [15].
Circadian clock genes and the circadian cycle
The basic genetic regulation of the circadian clock is
highly conserved across the animal kingdom. Most
mammalian clock genes were first identified via muta-
genic studies in fruit flies [16]. The core molecular clock
generates oscillations in protein levels via a series of
auto-regulatory transcriptional/translational feedback
loops [17]. Several clock genes encode transcription fac-
tors, with the molecular clock driving rhythmic expres-
sion of downstream clock-controlled genes [18].
The major components involved in this cellular clock
network include the transcriptional activators Circadian
Locomotor Output Cycles Kaput (CLOCK) and Brain
and muscle Arnt-like protein-1 (BMAL1). CLOCK has a
paralogue, Neuronal PAS domain protein 2 (NPAS2),
which compensates for loss of CLOCK in the SCN and
peripheral oscillators [19, 20]. The other main compo-
nents are Period (PER1 and PER2) and Cryptochrome
(CRY1 and CRY2), which form the negative arm of a
feedback loop [17]. Additional regulatory systems such
as nuclear hormone receptors and epigenetic mecha-
nisms have also been identified [21, 22].
Circadian gene expression is the result of a series of
transcription and translation events. This leads to the
expression of a different set of proteins that switches
them off at the end the day. The process then begins
again with timely removal of the repressors (PERs and
CRYs).
At the beginning of the circadian day, Bmal1 expres-
sion is driven by RORα, allowing the formation of
CLOCK/BMAL1 heterodimers (Fig. 1). This transcrip-
tion complex binds to CACGTG E-box sequences in the
promoters of the Per and Cry genes, increasing their ex-
pression. The CLOCK/BMAL1 complex also increases
expression of Rev-erbα, which suppresses Bmal1 tran-
scription [23]. The CLOCK/BMAL1-mediated increase
in Per and Cry expression allows for the accumulation of
PER in the cytosol, where it is phosphorylated by casein
Fig. 1 The core molecular circadian clock mechanism. Twenty-four-hour cellular rhythms are driven by an autoregulatory feedback loop. During
the subjective day, RORα contributes to expression of Bmal1 through its retinoic acid-related orphan receptor response element (RRE). The resulting
CLOCK/BMAL1 complex activates transcription of the negative regulators, Per and Cry. By the evening PER and CRY levels accumulate to form a protein
complex, which then becomes active as a CLOCK/BMAL1 inhibitor. During the subjective night, REV-ERBα suppresses expression of Bmal1, while the
newly formed PER/CRY complex blocks CLOCK/BMAL1 activity, thereby preventing further transcription from the Per and Cry genes. During this time,
the phosphorylated PER/CRY complex gradually degrades
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kinase 1ε and 1δ. Phosphorylated PER becomes ubiquiti-
nated and is readily degraded, but CRY accumulation al-
lows the formation of a stable PER/CRY/CK1 complex
[7]. This complex inhibits the transcriptional capacity of
CLOCK/BMAL1, preventing further expression of Per
and Cry, and also Rev-erbα. Eventually phosphorylated
PER and CRY are lost, de-repressing Bmal1 transcription
and allowing for higher levels of BMAL1 that start the
next circadian day [18].
Collectively these cycles ensure that the circadian
clock oscillates with a period of 24 hours, driven by the
appropriate environmental time cues (Fig. 1).
Peripheral circadian clocks
Peripheral tissues have their own intrinsic self-sustained
circadian oscillations, but are dependent on the central
clock and tissue-specific factors for synchronization.
Local cellular oscillators regulate specific circadian pro-
grammes of gene expression that vary according to tis-
sue function, with typically 5–10 % of all genes being
transcribed rhythmically [24].
Clock target genes can be controlled directly by the
CLOCK/BMAL1 complex, or indirectly via the circadian
expression of transcription factors. In this way, the circa-
dian clock confers a rhythmic aspect to a wide range of
tissues. In the breast, for example, the expression of
nearly 600 genes is controlled in a circadian manner.
The circadian regulation of gene expression impacts
upon many cellular processes and complex behaviours.
This is exemplified by SIRT1 and TIMELESS, proteins
that independently intersect the clock and the cell cycle
machines. For example, SIRT1 reduces proliferation by
deacetylating β-catenin [25] and binding p53 [26],
whereas TIMELESS advances the circadian clock in re-
sponse to DNA damage [27, 28].
The circadian system is therefore well integrated with
other physiologies. If the clock becomes disrupted, how-
ever, this can lead to disease [5].
Clock genes in breast biology
There is growing evidence that circadian clock gene
expression plays a role in breast biology. In mice, mu-
tations of specific circadian genes disrupt behavioural
and molecular rhythms. Such mutations also reveal the
involvement of cellular clocks in the initiation of
carcinogenesis.
Breast tissue contains a network of branched epithelial
ducts surrounded by a basement membrane, outside
which is a fibroblast-rich and adipose-rich stromal extra-
cellular matrix [29]. Clocks have been discovered within
breast epithelium using real-time bioluminescent imaging
of mammary explants from PER2::Luciferase [30] mice.
There are daily rhythmic variations in the expression of
core clock proteins BMAL1 and PER2. Moreover, during
the development of the gland from virgin through to full
lactation, tissue isolated at the same time of day reveals
that Bmal1 and Per1 mRNA levels increase in late preg-
nancy and lactation, while Per2 falls [31, 32].
The levels of clock gene expression are also controlled
by the breast tissue microenvironment. For example, we
have found that a stiff extracellular matrix such as is
found in ageing and cancer leads to suppression of core
clock rhythms. Intriguingly, local stiffness of the breast
stroma and extracellular matrix adjacent to breast epi-
thelium has a major role in determining cancer outcome
[33, 34]. The mechanisms linking the cell exterior to
clock control are not yet known, but could involve the
cytoskeleton and/or nuclear envelope proteins, one of
which regulates transcription of the Bmal1 gene [35].
The molecular clock is also crucial for regulating the
survival of stem cells. Indeed the self-renewal capacity of
mammary progenitor stem cells becomes compromised
in mice that have a defective CLOCK/BMAL1 complex,
revealing a circadian influence on breast function [36].
Studies in other tissues have demonstrated similar links
between the circadian clock and stem cells. For example,
undifferentiated neural stem cell cultures from BMAL1−/−
mice have an increased propensity to differentiate into glia
over neurons [37]. In addition, circadian oscillations in the
release of hematopoietic stem cells (HSCs), through
chemokine Cxcl12 and GSK3β, could result in a coordi-
nated release of cells and thereby repopulation of the bone
marrow stem cell niche [38].
Clock genes are expressed in normal breast. However,
their levels are variable and controlled both by the cellu-
lar microenvironment and by the developmental stage of
the tissue. Disruption of clock gene expression can in-
crease breast cancer risk (Table 1).
The role of circadian genes in breast cancer
Altered cell cycle and apoptosis
Per mutant mice have revealed a role for circadian gat-
ing of cells passing through the cell cycle. Indeed, an al-
tered Per gene contributes to malignancy. In humans,
there is reduced expression of Per genes in both sporadic
and familial breast cancer cells compared with normal
breast, perhaps occurring via methylation in regions of the
Per promoter [1]. In mice, Per2 loss-of-function mutations
exhibit higher tumour incidence and show greater suscep-
tibility to radiation-induced malignant lymphoma com-
pared with wild type [39].
Both PER1 and PER2 also promote apoptosis. Indeed
they may suppress breast cancer in vivo by inducing apop-
tosis [4] (Fig. 2). However, if there is decreased expression
of both Per1 and Per2 in breast tumours the action of PER
as a tumour suppressor becomes reduced. Moreover they
can indirectly suppress c-Myc transcription by inhibiting
E-box-mediated transactivation by BMAL1/Npas2 [32].
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Loss of Per2 leads to decreased apoptosis, and therefore
accumulation of damaged cells, by impairing p53 [40].
Consistent with this, Per2 overexpression in colon cancer
results in cell cycle arrest, growth inhibition and apoptosis
[41]. Additionally, Per2 mutants exhibit deregulation of c-
Myc, and its target cell-cycle genes CyclinD1 and Gadd45
[39, 42, 43]. Similarly, inhibition of PER1 alters expression
of key cell cycle regulators, by interacting with checkpoint
proteins ATM and Chk2, and Per1 overexpression can re-
duce proliferation in colon, lung and breast cancer cell
lines [41]. Intriguingly in U2OS cells, MYC can regulate
the circadian system by binding to E-box elements. High
levels of MYC expression dampen the circadian clock and
promote proliferation [43].
CRY proteins also impact tumorigenesis via the cell cycle.
The cell cycle suppressor WEE-1 is expressed in phase with
PER, during times of day when entry to the M phase is sup-
pressed [44]. However, mice deficient in the Cry genes have
de-regulated Wee-1 and CyclinD1, and therefore exhibit
disrupted cell cycle regulation. So far this has been shown
in liver cells, but has yet to be explored in breast tumours.
Disruption of PER and CRY therefore causes down-
regulation of growth control genes, implying a mechanistic
link between the circadian system and cell proliferation.
Moreover, these findings indicate that the circadian clock
is involved with both cell cycle control and apoptosis.
Altered cell metabolism
The circadian clock can also initiate and propagate cancer
through its effects on cell metabolism (Fig. 2). Metabolic
regulators SIRT1 and AMPK are cellular switches that alter
cell behaviour according to metabolic state, and both have
been linked to the circadian clock [45–47]. SIRT1 is a his-
tone deacetylase that is active under high levels of cellular
NAD+, and inactive under high levels of NADH [48]. SIRT1
deacetylates p53, inhibiting its activity and reducing apop-
tosis, which could have implications in cancer [49]. The cel-
lular ratio of NAD+ and the deacetylase activity of SIRT1
are both under circadian control [50]. They can feed back
into the core clock machinery and thereby regulate the cir-
cadian clock [51].
The cellular energy state is reflected in the ratio of
AMP + ADP:ATP. When ATP levels are low, AMPK is
phosphorylated by an upstream kinase [52]. In its active,
phosphorylated state, AMPK regulates many processes,
including glucose uptake, mitochondrial biogenesis, cell
proliferation and the circadian clock [53]. The cellular
clock regulates AMPK activity which in turn induces
degradation of the components of the negative arm of
the core clock loop, directly phosphorylating Cry1 and
inducing CK1-mediated degradation of Per2 [47, 54].
Clock disruption could directly impact SIRT1 and AMPK
signalling pathways, both of which are crucial in controlling
cell proliferation, apoptosis and tumour suppressor path-
ways. Furthermore, global disruption of circadian behaviour
by shift work, jet lag and ageing can affect the feeding
schedule of an individual. This could lead to energy imbal-
ances across the circadian cycle and further drive detrimen-
tal activity through these signalling pathways.
Single nucleotide polymorphisms
Breast cancer risk is also associated with single nucleo-
tide polymorphisms (SNPs) in Npas2 and Cry2, as well
as Clock [36]. Hypermethylation of the Clock promoter
Table 1 Genetic associations between circadian clocks and breast cancer
Mutation/SNP Possible mechanism Phenotype
CLOCK Self-renewal capacity of mammary progenitor cells
becomes compromised (our unpublished data)
Hypermethylation of Clock
promoter
Mediates CCL5 expression Reduced breast cancer risk [36]
NPAS2 Ala394Thr SNP Altered NPAS2 protein structure Increased breast cancer risk [55]
Per1 deficient Alters expression of checkpoint proteins ATM and Chk2 Increased proliferation [41]
Per1 overexpression Impairs p53 leading to decreased apoptosis, deregulation
of c-myc/CyclinD1/Gadd45
Reduces proliferation in colon, lung and breast cancer
cell lines [41]
Per2 deficient Increases OCT1 binding to EMT genes Slug, Snail and
Twist1
Higher tumour incidence, increased susceptibility to
radiation-induced malignant lymphoma [39]
Per2 overexpression Cell cycle arrest, growth inhibition, apoptosis induction Suppresses breast cancer in vivo [40, 41]
Per3 deficient Higher probability of cancer recurrence [7, 62]
Cry deficient Disrupted cell cycle regulation via de-regulation of Wee-1
and CyclinD1
BMAL1/Era/Per2 KO Prevents mammary acinar formation Facilitates invasion and metastasis [56]
BMAL1 overexpression Binds to p53 promoter Tumour suppression [61]
Circadian mutations covered in this review and their links to cancer. Both epidemiological and experimental data are included, along with possible mechanisms
and resultant phenotypes, where known
KO knockout, SNP single nucleotide polymorphism
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reduces breast cancer risk, with lower levels of CLOCK
in healthy controls. SNPs in Clock directly alter the
expression of genes linked to cell cycle progression, such
as CCL5. Similarly, Npas2 polymorphisms are associated
with increased breast cancer risk. The Ala394Thr SNP
alters the NPAS2 protein structure, which interferes with
NPAS2/BMAL1 heterodimerization. Women with this
SNP are at significantly higher risk of developing the
disease ([55], Table 1).
Link to oestrogen receptor
Per gene expression correlates with other genes impli-
cated in breast cancer, for example that encoding the
oestrogen receptor (ER). Oestrogen receptor interacts
with PER2 and BMAL1 and is integral to the formation
of mammary acini, which are the core cellular structures
within normal breast [56]. Mammary epithelial cells are
highly polarized, and proteins are differentially expressed
across the cells [57]. The polarity of the cells and acinar
stability are vital for directional milk secretion into
alveolar lumens [29]. However, knocking down PER2,
BMAL1, or ER prevents acinar formation, perhaps via a
feedback loop between oestrogen and the clock [56].
PER1 also influences ER transcriptional regulation, while
PER2 interacts with ER to suppress oestrogen-mediated
transcription of ER target genes [58]. Because Per is also
induced by oestrogen, there is a feedback loop coupling
the circadian clock and the oestrogen pathway. Absent ER
expression is associated with an aggressive tumour pheno-
type, and dysregulation of ER-transcriptional activity can
a
b
Fig. 2 Circadian disruption can drive breast cancer. a Intrinsic factors such as genetic defects or ageing, and extrinsic factors such as irregular shift
work, can severely disrupt the body’s internal timing system. b In turn these factors, either singularly or collectively, link a faulty circadian clock to
an increased risk of breast cancer. A faulty clock can directly disrupt the gating of the cell cycle and reduce apoptosis, These effects can also be
brought on indirectly through altered metabolism in response to a broken circadian clock. They can also lead to elevated EMT, driving the
formation of lethal metastases. A further mechanism that can link to breast cancer is arrhythmic production of melatonin, tipping the balance towards
tumorigenesis. EMT epithelial–mesenchymal transition
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equally lead to breast cancer [59]. PER may also act with
the breast cancer protein, BRCA1, to regulate ER tran-
scription [60].
Metastasis and epithelial–mesenchymal transition
Low-grade and non-metastasizing tumours maintain
functional circadian clocks. In more aggressive carcinomas,
however, the coordinated circadian oscillation of clock
genes becomes compromised [7]. For example, Bmal1 ex-
pression in the pancreas is significantly reduced in tumours,
correlating with cancer severity [61]. In the breast, PER and
CRY are associated with better prognosis in ER+/HER2–
tumours, yet CLOCK and NPAS2 are linked to better prog-
nosis in the more aggressive ER–/HER2– tumours. Further-
more, high expression of Clock, Per and Cry is associated
with longer metastasis-free survival [7]. In contrast, loss
of expression of the Per3 gene equates with tumours of
ER negativity, high histological grade and higher prob-
ability of recurrence [62]. Indeed, loss of PER3 and
CRY2 co-expression is associated with a higher risk of
breast cancer metastasis [7].
While altered levels of clock proteins may affect the
tissue structure and contribute to cellular transform-
ation, they also influence an epithelial–mesenchymal
transition (EMT) and thereby facilitate invasion and me-
tastasis (Fig. 2). For example, loss of PER2 could directly
drive EMT through OCT1. Under normal conditions,
PER2 recruits transcriptional co-repressors to OCT1-
binding promoters of EMT genes Twist1, Slug and Snail.
However, PER2 becomes deregulated in hypoxic, tumour-
like conditions, allowing EMT gene expression to be
activated [42].
Summary of the role of the clock in breast cancer
Together these studies show that clock gene defects in
mammary epithelium can lead to cell cycle disruption.
This disruption causes improper cell division, increased
susceptibility to breast cancer and leads to more aggres-
sive tumours. Although there are central roles for circa-
dian genes in normal breast biology, in the following we
discuss how disrupting the normal light/dark cycle can
also cause disease.
Shift work, night-time light exposure and breast
cancer
Over the last 20 years, epidemiological evidence has cor-
roborated a link between altered clocks and breast can-
cer. Women who work irregular shift patterns, such as
nurses, have a higher frequency of hormone-related
breast cancer [63–69], and the higher levels of cancer
may be greater for women who started night shifts be-
fore a first pregnancy [70]. Elevated breast cancer risk
also occurs in women exposed to high levels of ambient
light at night [71]. Irregular shift work refers to working
a mix of nights and days during a week. In these individ-
uals, the circadian clock has too little time to entrain to
the new shift pattern before it is changed again. Notably,
however, working consistently at night causes far less
disruption to the circadian rhythm.
Mice subjected to a simulated shift-work paradigm
have a significantly increased risk of acquiring mammary
tumours [72]. By inverting the light cycle every week,
mice acquired tumours faster than age-matched litter-
mates housed under normal light/dark cycles. Disruption
of sleep patterns, and thereby the internal body clock, of
shift workers therefore directly influences their physi-
ology and the rate of cancer development. Moreover,
working night shifts three or more times per month
elevates the risk of breast cancer in humans. This risk
increases with age and with more hours per week of
night-shift work [63, 66, 67, 73].
Constant light exposure during the night disturbs cir-
cadian pacemaker activity in the mammalian SCN. This
ultimately disrupts circadian rhythms throughout the
body. One mechanism may be through altered produc-
tion of the hormone melatonin. Night-time light expos-
ure reduces the rhythmic secretion of melatonin from
the pineal gland [74]. This hormone has oncostatic activ-
ity in experimental animals with mammary tumours,
and also in human breast cancer cells in culture [75]
(Fig. 2). Melatonin promotes genomic stability, and may
also have anti-invasive and anti-metastatic activity [76].
For example, in endocrine-responsive cancer, melatonin
reduces the expression and activity of aromatase, which
normally converts testosterone to oestrogen. The onco-
static action of melatonin on hormone-dependent mam-
mary tumours is mainly based on its anti-estrogenic
actions, both reducing biosynthesis of oestrogen from an-
drogens and neutralizing the cellular effects of oestrogen.
Rats exposed to small amounts of light at night, rather
than no light, had disrupted melatonin profiles and faster-
growing mammary tumours that were tamoxifen resistant;
this could be reversed by melatonin supplementation [77].
In humans, reduction of nocturnal melatonin levels may
increase the effects of oestrogen and thereby contribute
to breast cancer risk—and indeed, make tumours in-
sensitive to steroid therapy. Epidemiological studies in
nurses also reveal that shift work induces a significant
increase in circulating oestradiol levels, which could
further disrupt mammary oestrogen signalling and thereby
promote cancer [78].
Another potential mechanism linking altered light ex-
posure at night-time to breast cancer risk could be via
the circadian regulation of micro-RNA (miRNA) expres-
sion. Several miRNAs known to be involved with breast
cancer risk show fluctuations during the day. For ex-
ample, the levels of miR-150-5p and miR-133a-3p are
dramatically altered by circadian disruption [79]. Some
Blakeman et al. Breast Cancer Research  (2016) 18:89 Page 6 of 9
of these miRNAs are interconnected with the expression
of proteins known to have roles in breast cancer, such as
NFkB and Stat3. The levels of some transcripts that en-
code proteins involved with cancer are also altered in
circadian-disrupted mice [80].
Night-time light exposure can also happen as a result
of loss of rhythmic behaviour, such as in SCN-lesioned
animals. This both increases the risk of tumour forma-
tion and enhances progression of pre-existing tumours.
For example, in SCN-ablated mice that are inoculated
with implants of osteosarcoma or pancreatic adenocar-
cinoma, tumours grow two to three times faster than in
sham-operated comparators [8]. In the breast, a robust
circadian rhythm is associated with slow-growing tu-
mours, while altered rhythms are linked to faster grow-
ing tumours [81, 82].
Together the evidence suggests that disrupting circa-
dian clocks via night-time light exposure has an adverse
role on tumour progression. This applies to those work-
ing irregular shift patterns, although it is still controver-
sial whether there are links in flight attendant jet lag
[83] or whether the widespread use of electric lighting at
night might contribute to breast cancer [84].
The mechanisms by which altered light exposure con-
tributes to cancer are not yet understood fully. However,
the link between circadian disruption and breast cancer
may have profound societal importance.
Conclusion
Tissue-based oscillators within the breast are coordi-
nated by the SCN, and are influenced by photic, endo-
crine, neural and metabolic cues. Analysis of the strong
circadian component within the breast has highlighted
its influence on the cell cycle, which impacts on tumour
progression and carcinoma aggression.
In-vivo evidence has revealed the role of the circadian
molecular clockwork in tumour suppression, highlight-
ing that breast cancer should no longer be treated as a
local disorder but rather can result from systemic defects
in tissue control.
Mouse models have demonstrated the importance of
core clock genes within the breast, whether that is in
progenitor cell renewal, tumour incidence, or interaction
with the oestrogen pathway. Collectively, this indicates
that there is an oncostatic role of some clock genes.
Together with the epidemiological data linking an in-
creased incidence of breast cancer in shift workers, this
has serious implications for the demands of modern so-
ciety. Circadian disruption imposes a major public health
issue that has yet to receive the recognition it deserves.
Nocturnal lifestyles perturb the normal patterns of
circadian behaviour, resulting in detrimental effects on
clock-controlled physiological and metabolic pathways.
Increased public awareness of the circadian influences
on breast cancer risk could enhance lifestyle choices, as
well as improve the alignment of physiological systems
with the daily body clock.
There is still a fair way to go in characterizing the mo-
lecular basis of how the circadian system influences
breast cancer, and which of the different genetic types of
breast cancer are most influenced by altered clocks. Fur-
ther delineation of the mechanisms linking clock genes
to cancer is needed in order to fully understand how an
altered circadian system and how rotating shift work in-
fluence the disease. This knowledge will help to improve
future therapeutic interventions.
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